Impax regains rights to Parkinson's disease drug candidate

04/30/2013 | Reuters

Impax Laboratories will regain the rights to develop and market IPX066, an experimental Parkinson's disease drug, in certain countries after agreeing to end a collaboration deal with GlaxoSmithKline. The firms cited regulatory and commercialization delays in countries where GSK holds the right to sell the drug, known as Rytary in the U.S., as the reason for the deal's termination.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX